Compare BRBS & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BRBS | NGEN |
|---|---|---|
| Founded | 1893 | 2017 |
| Country | United States | Canada |
| Employees | N/A | 14 |
| Industry | Commercial Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 392.4M | 337.4M |
| IPO Year | 2015 | N/A |
| Metric | BRBS | NGEN |
|---|---|---|
| Price | $3.62 | $3.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 597.5K | 239.4K |
| Earning Date | 04-23-2026 | 04-02-2026 |
| Dividend Yield | ★ 23.48% | N/A |
| EPS Growth | ★ 135.48 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $111,284,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $33.00 | ★ N/A |
| Revenue Growth | ★ 123.99 | N/A |
| 52 Week Low | $3.33 | $3.51 |
| 52 Week High | $4.79 | $5.93 |
| Indicator | BRBS | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 37.97 | 42.08 |
| Support Level | $3.42 | $3.65 |
| Resistance Level | $4.38 | $4.44 |
| Average True Range (ATR) | 0.08 | 0.20 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 17.33 | 6.78 |
Blue Ridge Bankshares Inc is a United States-based company engaged in offering commercial and consumer banking and financial services through its wholly-owned bank subsidiary, Blue Ridge Bank, National Association, and its non-bank financial services affiliates. The bank offers services such as checking accounts, savings accounts, money market accounts, cash management accounts, commercial and industrial loans, residential mortgages, commercial mortgages, home equity loans, consumer installment loans, investment accounts, insurance and others. It has three reportable business segments: commercial banking, mortgage banking, and holding company activities.
NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.